TGTX today
$64.56-$1.20 (-1.82%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourBearish
15 minBearish
5 minBearish
Daily trend turns down below $45.37
Key levels
Support$63.60
Support$58.92
Latest news & SEC filings
AnalystEvercore ISI keeps Outperform rating on TG Therapeutics, cuts target to $71
EarningsTG Therapeutics holds Q3 2026 earnings call
EarningsTG Therapeutics lifts FY guidance after Q3 2026 report
All TGTX news →About TG Therapeutics
TG Therapeutics develops and sells medicines that target B-cell driven illnesses. Its lead drug, BRIUMVI, is an antibody against CD20 that regulators have cleared for adults with relapsing multiple sclerosis, sold directly in the United States and through a partner in Europe and other regions. The company is also testing a subcutaneous version of the drug and azer-cel in progressive MS and myasthenia gravis. Its customers are neurologists, clinics, and patients.
Based on the company's 10-K filed Feb 27, 2026.
Nasdaq · Healthcare
TG THERAPEUTICS, INC. (TGTX)
What Is the Price Target for TGTX?
SEPT Low Target
$71.00
SEPT Mid Target
$77.00
SEPT High Target
$86.00
Analyst Consensus
$77.00
Is TGTX a Buy or Sell Right Now?
Thesis
- •Revenue growing 87.3% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TGTX.
Start Free Trial →Is TGTX Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$57.26
52
Moat Score
NARROW
4/9
Piotroski Score
14.0
Altman Z-Score
What Is Smart Money Doing with TGTX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TGTX Growth Story
Revenue YoY
87.3%
3yr Revenue CAGR
504.9%
EPS Growth YoY
1746.67%
FCF Growth YoY
38.4%
Revenue Trend
STRONG
Dark Pool Trades for TGTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TGTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:38 | $64.56 | 4,138 | $$267K | SELL |
| 21:00:32 | $64.56 | 2,602 | $$168K | SELL |
| 21:00:32 | $64.56 | 2,653 | $$171K | SELL |
| 21:00:32 | $64.56 | 6,678 | $$431K | SELL |
| 21:00:01 | $64.56 | 1,441 | $$93K | SELL |
5 dark pool trades shown · $$1.1M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for TGTX
PREVIEWSEPT Investing provides real-time options flow tracking for TGTX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $65 | Jan 15 | 64 | $$5300 | 10 | SWEEP |
| PUT | $65 | Jan 15 | 64 | $$2650 | 5 | SWEEP |
| PUT | $65 | Jan 15 | 64 | $$15.4K | 29 | SWEEP |
| PUT | $65 | Jan 15 | 64 | $$1060 | 2 | SWEEP |
| PUT | $65 | Jan 15 | 64 | $$3180 | 6 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for TG THERAPEUTICS, INC. (TGTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TGTX — frequently asked questions
What is TGTX stock price today?
TG THERAPEUTICS, INC. (TGTX) is at $64.56, down 1.82% (-$1.20) at the Nov 12, 2026 close.
Why is TGTX stock moving today?
Latest TGTX news — Nov 10, 2026: Evercore ISI keeps Outperform rating on TG Therapeutics, cuts target to $71 · Nov 9, 2026: TG Therapeutics holds Q3 2026 earnings call
Why did TGTX stock move on Nov 9, 2026?
TG Therapeutics reported third-quarter 2026 results that beat expectations, posting earnings of $0.35 per share versus the $0.34 consensus and revenue of $259.936 million against the $245.475 million estimate. The company also raised its full-year 2026 sales guidance to $1.000 billion from $950.000 million, topping the $960.306 million consensus.
What is the TGTX price target?
The average analyst price target for TGTX is $77.00, ranging from $71 to $86, based on 5 analysts. Latest: Evercore ISI Group maintains on Nov 10, 2026.
What do analysts rate TGTX?
Analyst ratings for TGTX: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did TGTX beat earnings?
TGTX last reported on Nov 9, 2026: EPS $0.35 vs $0.34 expected — a beat of 2.9%.
What is TGTX's P/E ratio?
TGTX trades at a P/E of 23.1 vs a Healthcare average of 17.1.
Does TGTX pay a dividend?
TGTX does not currently pay a dividend.
What are TGTX support and resistance levels?
Support: $63.60, $58.92, $54.60.
What are insiders doing with TGTX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on TGTX?
Nov 10, 2026: Evercore ISI keeps Outperform rating on TG Therapeutics, cuts target to $71 · Nov 9, 2026: TG Therapeutics holds Q3 2026 earnings call · Nov 9, 2026: TG Therapeutics lifts FY guidance after Q3 2026 report